查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1884056

前列腺癌疫苗市場規模、佔有率、成長及全球產業分析：依類型、應用和地區劃分的洞察與預測（2024-2032 年）

Prostate Cancer Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 169 Pages | 商品交期: 請詢問到貨日

價格

前列腺癌疫苗市場成長推動因素

由於疾病盛行率上升、公眾意識增強以及個人化免疫療法的廣泛應用，全球前列腺癌疫苗市場正經歷快速增長。根據最近的一項研究，2024 年該市場規模為 4.904 億美元，預計到 2025 年將達到 5.339 億美元。預計到 2032 年將進一步成長至 11.836 億美元，預測期內複合年增長率 (CAGR) 為 12.0%。北美地區在2024年佔市場主導地位，市佔率高達79.79%，這主要得益於其完善的醫療保健基礎設施、免疫療法的廣泛應用以及人們對前列腺癌治療方案的高度認知。

攝護腺癌疫苗並非預防性疫苗，而是用於治療已確診的疾病。這些疫苗能夠活化攻擊前列腺癌細胞的免疫細胞，旨在根除復發性疾病或延緩疾病進展。目前，Dendreon Pharmaceuticals LLC. 的 PROVENGE（Sipuleucel-T）是唯一獲得FDA批准的疫苗，鞏固了其在北美市場的領先地位。對標靶性強、毒性小的療法的需求不斷增長，以及荷爾蒙療法和化療等傳統療法的局限性，正在推動市場進一步擴張。

根據世界癌症研究基金會預測，2022年全球將新增1,467,854例前列腺癌病例，凸顯了開發有效療法的迫切性。免疫療法因其副作用小、療效持久且可與傳統療法聯合應用，在治療前列腺癌方面正得到越來越廣泛的應用。

市場推動因素與機會

關鍵推動因素是晚期前列腺癌對荷爾蒙療法的抗藥性。雄性激素剝奪療法 (ADT) 可降低睪固酮水平，但由於雄性激素受體突變，腫瘤會隨著時間的推移產生抗藥性。加州大學洛杉磯分校 Jonsson 綜合癌症中心 2023 年 12 月的一項研究揭示了前列腺細胞的不同類型——基底細胞和腔細胞——這表明需要針對對激素療法反應較差的腫瘤開發替代療法。這推動了對疫苗的需求。

此外，個人化免疫療法的未滿足需求也帶來了巨大的市場機會。各公司正投資研發新型候選疫苗，包括病毒疫苗和 DNA 疫苗。 2024年12月，Candel Therapeutics公佈了其病毒免疫療法CAN-2409聯合放射療法的III期臨床試驗的積極結果，證實其對中高危險局限性前列腺癌患者有效。這些進展凸顯了市場的成長潛力以及持續研發投入的必要性。

市場阻礙因素與挑戰

疫苗複雜且耗時的給藥流程是主要阻礙因素。 Provenge需要進行白血球分離術、集中細胞處理和回輸，大約需要四天時間。這種勞動密集型流程可能會因物流挑戰、病患依從性問題和成本增加而限制其廣泛應用。

此外，市場還面臨監管挑戰和較高的臨床試驗失敗率。對細胞療法的嚴格監管往往會延遲其審批和商業化進程。例如，Ventac Partners 公司的抗原疫苗 RV001 因療效不足，於 2022 年 5 月的 II 期臨床試驗中失敗，凸顯了前列腺癌疫苗相關的財務和研發風險。

市場趨勢

一個值得關注的趨勢是開發旨在誘導強效抗腫瘤免疫反應的 DNA 疫苗。例如，Madison Vaccines 公司的 MVI-118 疫苗靶向轉移性去勢敏感性前列腺癌的雄性激素受體配體結合域。臨床前和早期臨床試驗已證實其安全性、耐受性和延長疾病進展間隔，這反映了核酸技術在免疫療法中日益重要的作用。與其他療法（包括免疫檢查點抑制劑，例如 ADT 和 Keytruda）合併使用的情況越來越普遍。

市場區隔分析

  • 依產品劃分：PROVENGE（Sipulcel-T）將主導市場，憑藉其獲得 FDA 批准以及在晚期疾病中的療效，預計將在 2024 年佔最大的市場佔有率。 "其他" 細分市場預計將穩定成長，因為 PCA001 和 VTP-850 等新型臨床階段疫苗將進入研發管線。
  • 依最終用戶劃分：擁有專門用於白血球分離、細胞處理和疫苗接種的基礎設施的醫院引領市場。隨著免疫療法的普及，專科診所和研究中心也正在成為重要的應用者。

區域展望

  • 北美：預計到 2024 年，市場規模將達到 3.913 億美元。該地區的優勢包括龐大的老年風險族群、先進的輸液中心以及完善的健保報銷體系。大部分疫苗將在美國普及。
  • 歐洲：第二大市場，主要得益於公眾意識的提高和積極的篩檢項目，例如匈牙利和義大利的 "Movember" 活動。
  • 亞太地區：預計成長最快，這主要歸功於前列腺癌發生率的上升以及澳洲等國家前列腺護理中心的建立。
  • 拉丁美洲、中東和非洲：由於大眾意識較低且前列腺癌疫苗價格較高，預計成長速度將放緩。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場推動因素
  • 市場阻礙因素
  • 市場機遇
  • 市場趨勢

第四章：主要發現

  • 2024年主要國家及地區攝護腺癌盛行率
  • 主要公司產品線分析
  • 市場技術進步
  • 主要公司新產品發布
  • 主要產業趨勢（併購、合作等）

第五章：全球前列腺癌疫苗市場分析、洞察與預測 (2019-2032)

  • 市場分析、洞察與預測 - 依產品分類
    • PROVENGE (Sipoleucel-T)
    • 其他
  • 市場分析、洞察與預測 - 依最終用戶分類
    • 醫院
    • 專科診所
    • 其他
  • 市場分析、洞察與預測 - 依地區分類
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章：北美前列腺癌疫苗市場分析、洞察與預測 (2019-2032)

  • 依國家分類
    • 美國各州
    • 加拿大

第七章 歐洲前列腺癌疫苗市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲國家

第八章 亞太地區前列腺癌疫苗市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 其他亞太地區國家

第九章 拉丁美洲前列腺癌疫苗市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第十章：中東和非洲前列腺癌疫苗市場分析、洞察與預測（2019-2032）

  • 依國家劃分
    • 海灣合作委員會
    • 南非
    • 其他中東和非洲國家

第十一章：競爭分析

  • 全球市佔率分析（2024）
  • 公司簡介
    • Dendreon Pharmaceuticals LLC.
    • Barinthus 生物治療公司
    • 坎德爾療法有限公司
    • 生物科技
    • 麥迪遜疫苗公司
Product Code: FBI113610

Growth Factors of prostate cancer vaccines Market

The global prostate cancer vaccines market is experiencing rapid growth due to rising disease prevalence, increasing awareness, and expanding adoption of personalized immunotherapies. According to recent insights, the market was valued at USD 490.4 million in 2024, is projected to reach USD 533.9 million in 2025, and is expected to grow to USD 1,183.6 million by 2032, reflecting a CAGR of 12.0% during the forecast period. North America dominated the market in 2024 with a 79.79% share, primarily due to well-established healthcare infrastructure, widespread access to immunotherapy, and higher awareness about prostate cancer treatment options.

Prostate cancer vaccines are therapeutic, targeting existing disease rather than prevention. The vaccines aim to activate immune cells capable of attacking prostate cancer cells, either to eradicate recurrent disease or delay disease progression. Currently, PROVENGE (Sipuleucel-T) by Dendreon Pharmaceuticals LLC. remains the only FDA-approved vaccine, reinforcing North America's leadership in the market. Rising demand for targeted, low-toxicity therapies and the limitations of traditional treatments such as hormone therapy and chemotherapy further propel market expansion.

According to the World Cancer Research Fund, 1,467,854 new prostate cancer cases were reported globally in 2022, emphasizing the urgent need for effective therapies. Immunotherapy offers durable responses with fewer side effects and can be combined with conventional treatments, enhancing its adoption in prostate cancer care.

Market Drivers and Opportunities

A key driver is the resistance to hormone therapy observed in advanced prostate cancer. Androgen deprivation therapy (ADT) reduces testosterone levels, yet tumors may develop resistance over time due to mutations in androgen receptors. Research from UCLA Jonsson Comprehensive Cancer Center in December 2023 revealed distinct basal and luminal prostate cells, highlighting that tumors less responsive to hormone therapy require alternative treatments, thereby increasing demand for vaccines.

Furthermore, the unmet need for personalized immunotherapies provides significant market opportunities. Companies are investing in novel vaccine candidates, including viral and DNA-based vaccines. In December 2024, Candel Therapeutics, Inc. reported positive Phase 3 results for CAN-2409 viral immunotherapy, combined with radiation therapy, demonstrating efficacy in intermediate-to-high-risk localized prostate cancer patients. Such developments highlight the market's growth potential and ongoing R&D investment.

Market Restraints and Challenges

The complex and lengthy administration of vaccines is a major restraint. Provenge requires leukapheresis, cell processing at a centralized facility, and reinfusion, spanning approximately four days. This labor-intensive process may limit adoption due to logistical challenges, patient compliance, and increased costs.

Additionally, the market faces regulatory challenges and high clinical trial failure rates. Strict regulations for cellular therapies often delay approvals and commercialization. For example, Ventac Partners' RV001 antigen-based vaccine failed its Phase 2 trial in May 2022 due to insufficient efficacy, illustrating the financial and developmental risks associated with prostate cancer vaccines.

Market Trends

A prominent trend is the development of DNA-based vaccines, designed to trigger potent anti-tumor immune responses. Vaccines such as MVI-118 by Madison Vaccines, Inc. target the androgen receptor ligand-binding domain for metastatic castration-sensitive prostate cancer. Preclinical and early clinical trials demonstrated safety, tolerability, and prolonged disease progression intervals, reflecting the growing role of nucleic acid technologies in immunotherapy. Integration with other therapies, including ADT and checkpoint inhibitors like Keytruda, is becoming increasingly common.

Segmentation Analysis

  • By Product: PROVENGE (Sipuleucel-T) dominates, accounting for the largest market share in 2024 due to FDA approval and efficacy in advanced cases. The "others" segment is projected to grow steadily with new clinical-stage vaccines like PCA001 and VTP-850 entering development pipelines.
  • By End User: Hospitals lead the market due to specialized infrastructure required for leukapheresis, cell processing, and vaccine administration. Specialty clinics and research centers are emerging as important adopters as immunotherapy access expands.

Regional Outlook

  • North America: Valued at USD 391.3 million in 2024, the region benefits from a geriatric population at high risk, advanced infusion centers, and comprehensive reimbursement frameworks. The U.S. accounts for the majority of adoption.
  • Europe: The second-largest market, driven by rising awareness campaigns and proactive testing programs such as the "Movember" initiatives in Hungary and Italy.
  • Asia Pacific: Poised for the fastest growth due to increasing prostate cancer prevalence and the establishment of prostate care centers in countries like Australia.
  • Latin America & Middle East & Africa: Exhibit slower growth due to high costs and limited awareness of prostate cancer vaccines.

Competitive Landscape

The market is highly consolidated, with Dendreon Pharmaceuticals LLC. leading due to PROVENGE. Other key players, including Barinthus Biotherapeutics, Candel Therapeutics, Inc., BioNTech, and Madison Vaccines, Inc., are advancing R&D pipelines and clinical trials to expand market presence and introduce novel vaccine candidates.

Conclusion

With a market size of USD 490.4 million in 2024, expected to reach USD 533.9 million in 2025, and projected to hit USD 1,183.6 million by 2032, the prostate cancer vaccines market is poised for substantial growth. Drivers include rising prevalence, resistance to hormonal therapies, and innovation in immunotherapy platforms, while regulatory complexity and administration challenges remain key hurdles. Continuous R&D, DNA-based vaccines, and expansion of treatment centers will shape market dynamics through 2032.

Segmentation By Product

  • PROVENGE (sipuleucel-T)
  • Others

By End User

  • Hospitals
  • Specialty Clinics
  • Others

By Geography

  • North America (By Product, End User, and Country )
    • U.S.
    • Canada
  • Europe (By Product, End User, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific (By Product, End User, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America (By Product, End User, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product, End User, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Prostate Cancer - by Key Countries/Regions, 2024
  • 4.2. Pipeline Analysis, by Key Players
  • 4.3. Technological Advancements in Market
  • 4.4. New Product Launches, by Key Players
  • 4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)

5. Global Prostate Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. PROVENGE (sipoleucel-T)
    • 5.1.2. Others
  • 5.2. Market Analysis, Insights and Forecast - By End User
    • 5.2.1. Hospitals
    • 5.2.2. Specialty Clinics
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - Region
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. Asia Pacific
    • 5.3.4. Latin America
    • 5.3.5. Middle East & Africa

6. North America Prostate Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. PROVENGE (sipoleucel-T)
    • 6.1.2. Others
  • 6.2. Market Analysis, Insights and Forecast - By End User
    • 6.2.1. Hospitals
    • 6.2.2. Specialty Clinics
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Country
    • 6.3.1. U.S.
    • 6.3.2. Canada

7. Europe Prostate Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. PROVENGE (sipoleucel-T)
    • 7.1.2. Others
  • 7.2. Market Analysis, Insights and Forecast - By End User
    • 7.2.1. Hospitals
    • 7.2.2. Specialty Clinics
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.3.1. Germany
    • 7.3.2. U.K.
    • 7.3.3. France
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Rest of Europe

8. Asia Pacific Prostate Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. PROVENGE (sipoleucel-T)
    • 8.1.2. Others
  • 8.2. Market Analysis, Insights and Forecast - By End User
    • 8.2.1. Hospitals
    • 8.2.2. Specialty Clinics
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. India
    • 8.3.4. Australia
    • 8.3.5. Rest of Asia Pacific

9. Latin America Prostate Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. PROVENGE (sipoleucel-T)
    • 9.1.2. Others
  • 9.2. Market Analysis, Insights and Forecast - By End User
    • 9.2.1. Hospitals
    • 9.2.2. Specialty Clinics
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.3.1. Brazil
    • 9.3.2. Mexico
    • 9.3.3. Rest of Latin America

10. Middle East & Africa Prostate Cancer Vaccines Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Product
    • 10.1.1. PROVENGE (sipoleucel-T)
    • 10.1.2. Others
  • 10.2. Market Analysis, Insights and Forecast - By End User
    • 10.2.1. Hospitals
    • 10.2.2. Specialty Clinics
    • 10.2.3. Others
  • 10.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.3.1. GCC
    • 10.3.2. South Africa
    • 10.3.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. Dendreon Pharmaceuticals LLC.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. Financials (Based on Availability)
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. SWOT,Etc.
    • 11.2.2. Barinthus Biotherapeutics
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. Financials (Based on Availability)
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. SWOT,Etc
    • 11.2.3. Candel Therapeutics, Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. Financials (Based on Availability)
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. SWOT,Etc
    • 11.2.4. BioNTech
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. Financials (Based on Availability)
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. SWOT,Etc
    • 11.2.5. Madison Vaccines, Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. Financials (Based on Availability)
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. SWOT,Etc

List of Tables

  • Table 1: Global Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by Product, 2019-2032
  • Table 2: Global Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 3: Global Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by Region, 2019-2032
  • Table 4: North America Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by Product, 2019-2032
  • Table 5: North America Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 6: North America Prostate Cancer Vaccines Market Revenue (USD million) Forecast, By Country, 2019-2032
  • Table 7: Europe Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by Product, 2019-2032
  • Table 8: Europe Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 9: Europe Prostate Cancer Vaccines Market Revenue (USD million) Forecast, By Country/ Sub-region, 2019-2032
  • Table 10: Asia Pacific Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by Product, 2019-2032
  • Table 11: Asia Pacific Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 12: Asia Pacific Prostate Cancer Vaccines Market Revenue (USD million) Forecast, By Country/ Sub-region, 2019-2032
  • Table 13: Latin America Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by Product, 2019-2032
  • Table 14: Latin America Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 15: Latin America Prostate Cancer Vaccines Market Revenue (USD million) Forecast, By Country/ Sub-region, 2019-2032
  • Table 16: Middle East & Africa Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by Product, 2019-2032
  • Table 17: Middle East & Africa Prostate Cancer Vaccines Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 18: Middle East & Africa Prostate Cancer Vaccines Market Revenue (USD million) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Prostate Cancer Vaccines Market Revenue Breakdown (USD million, %) by Region, 2024 & 2032
  • Figure 2: Global Prostate Cancer Vaccines Market Value Share (%), by Product, 2024 & 2032
  • Figure 3: Global Prostate Cancer Vaccines Market Value Share (%), by End User, 2024 & 2032
  • Figure 4: Global Prostate Cancer Vaccines Market Value Share (%), by Region, 2024 & 2032
  • Figure 5: North America Prostate Cancer Vaccines Market Value (USD million), by Product, 2024 & 2032
  • Figure 6: North America Prostate Cancer Vaccines Market Value Share (%), by Product, 2024
  • Figure 7: North America Prostate Cancer Vaccines Market Value (USD million), by End User, 2024 & 2032
  • Figure 8: North America Prostate Cancer Vaccines Market Value Share (%), by End User, 2024
  • Figure 9: North America Prostate Cancer Vaccines Market Value (USD million), By Country, 2024 & 2032
  • Figure 10: North America Prostate Cancer Vaccines Market Value Share (%), By Country, 2024
  • Figure 11: Europe Prostate Cancer Vaccines Market Value (USD million), by Product, 2024 & 2032
  • Figure 12: Europe Prostate Cancer Vaccines Market Value Share (%), by Product, 2024
  • Figure 13: Europe Prostate Cancer Vaccines Market Value (USD million), by End User, 2024 & 2032
  • Figure 14: Europe Prostate Cancer Vaccines Market Value Share (%), by End User, 2024
  • Figure 15: Europe Prostate Cancer Vaccines Market Value (USD million), By Country/ Sub-region, 2024 & 2032
  • Figure 16: Europe Prostate Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 17: Asia Pacific Prostate Cancer Vaccines Market Value (USD million), by Product, 2024 & 2032
  • Figure 18: Asia Pacific Prostate Cancer Vaccines Market Value Share (%), by Product, 2024
  • Figure 19: Asia Pacific Prostate Cancer Vaccines Market Value (USD million), by End User, 2024 & 2032
  • Figure 20: Asia Pacific Prostate Cancer Vaccines Market Value Share (%), by End User, 2024
  • Figure 21: Asia Pacific Prostate Cancer Vaccines Market Value (USD million), By Country/ Sub-region, 2024 & 2032
  • Figure 22: Asia Pacific Prostate Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 23: Latin America Prostate Cancer Vaccines Market Value (USD million), by Product, 2024 & 2032
  • Figure 24: Latin America Prostate Cancer Vaccines Market Value Share (%), by Product, 2024
  • Figure 25: Latin America Prostate Cancer Vaccines Market Value (USD million), by End User, 2024 & 2032
  • Figure 26: Latin America Prostate Cancer Vaccines Market Value Share (%), by End User, 2024
  • Figure 27: Latin America Prostate Cancer Vaccines Market Value (USD million), By Country/ Sub-region, 2024 & 2032
  • Figure 28: Latin America Prostate Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 29: Middle East & Africa Prostate Cancer Vaccines Market Value (USD million), by Product, 2024 & 2032
  • Figure 30: Middle East & Africa Prostate Cancer Vaccines Market Value Share (%), by Product, 2024
  • Figure 31: Middle East & Africa Prostate Cancer Vaccines Market Value (USD million), by End User, 2024 & 2032
  • Figure 32: Middle East & Africa Prostate Cancer Vaccines Market Value Share (%), by End User, 2024
  • Figure 33: Middle East & Africa Prostate Cancer Vaccines Market Value (USD million), By Country/ Sub-region, 2024 & 2032
  • Figure 34: Middle East & Africa Prostate Cancer Vaccines Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 35: Global Prostate Cancer Vaccines Market Share (%), By Company, 2024